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Abstract (n=223) 72 
Given that high-risk human papillomavirus (HPV) is the necessary cause of virtually all cervical 73 
cancer, the clinical meaning of HPV-negative cervical precancer is unknown. We therefore 74 
conducted a literature search in Ovid MEDLINE, PubMed Central®, and Google Scholar to 75 
identify English-language studies in which 1) HPV-negative and positive, histologically 76 
confirmed cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) were 77 
detected and 2) summarized statistics or de-identified individual data were available to 78 
summarize proportions of biomarkers indicating risk of cancer. Nineteen studies including 3,089 79 
(91.0%) HPV-positive and 307 (9.0%) HPV-negative CIN2+ were analyzed. HPV-positive 80 
CIN2+ (vs. HPV-negative CIN2+) was more likely to test positive for biomarkers linked to 81 
cancer risk: a study diagnosis of CIN3+ (vs. CIN2) (18 studies, 0.56 vs. 0.24, p<0.001) 82 
preceding HSIL+ cytology (15 studies, 0.54 vs. 0.10, p<0.001); and high-grade colposcopic 83 
impression (13 studies, 0.30 vs. 0.18, p=0.03). HPV-negative CIN2+ was more likely to test 84 
positive for low-risk HPV genotypes than HPV-positive CIN2+ (p<0.001). HPV-negative CIN2+ 85 
appears to have lower cancer risk than HPV-positive CIN2+. Clinical studies of human high-risk 86 
HPV testing for screening to prevent cervical cancer may refer samples of HPV test-negative 87 
women for disease ascertainment to correct verification bias in the estimates of clinical 88 
performance. However, verification-bias adjustment of the clinical performance of HPV testing 89 
may over-correct/underestimate its clinical performance to detect truly precancerous 90 
abnormalities.  91 
 
6 
 
Introduction 92 
The discovery that specific, high-risk human papillomavirus (HPV) genotypes cause virtually all 93 
cervical cancer, as well as most anal, vaginal, vulvar, and penile cancers, and a significant 94 
proportion of oropharyngeal cancers, has led to changes in how we prevent these cancers, 95 
including prophylactic HPV vaccination for primary prevention and HPV detection screening for 96 
secondary prevention of cervical cancer. Of the latter, there are now several HPV tests that have 97 
FDA approval for cervical screening either alone (“primary HPV testing”) or in combination 98 
with concurrent cytologic/Pap testing (“co-testing”). The primary advantage of including HPV 99 
detection in routine cervical screening is that a negative HPV test or co-test provides better 100 
reassurance against cervical cancer and its immediate precursor abnormalities, cervical 101 
intraepithelial neoplasia (CIN) grade 3 (CIN3), CIN grade 2 (CIN2), and adenocarcinoma in situ 102 
(AIS)(1-6). Thus, using an HPV test in routine cervical screening safely allows for a lengthening 103 
of screening intervals between negative results. 104 
In theory, calculation of diagnostic performance indices, such as sensitivity and specificity, must 105 
take into account the possibility of verification bias, which results from unequal verification of 106 
the presence of disease between test positive and test negative subjects (7-10). Clinical trials to 107 
evaluate the accuracy of HPV and other screening tests often have included verification-bias 108 
adjustment (VBA) in the study design. VBA is an imputation method intended to correct for the 109 
inability of the investigator to verify the presence of disease among those who tested negative on 110 
screening. It relies on randomly sampling those who were in the latter category, and reweighting 111 
before calculating test performance, to simulate complete disease ascertainment. 112 
This is accomplished by sending subjects/patients with negative screening test results for further 113 
evaluation by colposcopy and biopsy. Using the sampling fraction, one can then estimate via 114 
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extrapolation the number of true negative (TN) and false negative (FN) cases, thus enabling the 115 
reconstitution of the unobserved underlying 2x2 table that would ideally be used to measure the 116 
clinical performance of the test under evaluation. 117 
Although VBA is a standard statistical method used in screening studies, one caveat is that it 118 
assumes that the cases with FN and true–positive (TP) results have the same clinical/biological 119 
importance. In the case of cancer prevention, this would mean that FN and TP cases have similar 120 
invasive or oncogenic potential. Specifically, for the evaluation of an HPV test, this would imply 121 
that HPV-negative (FN-test) CIN2 or more severe (CIN2+) cervical abnormalities have similar 122 
risk of becoming invasive cervical cancer as HPV-positive (TP-test) CIN2+. As an example of 123 
the impact on VBA, the crude versus VBA-adjusted sensitivity of high-risk HPV by the cobas 124 
test (Roche Molecular Systems, Pleasanton, CA, USA) for CIN2+ was 92.0% and 75.1%, 125 
respectively (11). 126 
However, given that high-risk HPV causes virtually all cervical cancer, the clinical meaning of 127 
HPV-negative CIN2/3 is uncertain, particularly given the subjective nature of both the 128 
colposcopic impression that guides sampling for diagnostic biopsy (12-16) and the 129 
histopathologic interpretation of the tissue sample (17-21). Therefore, it is unclear whether these 130 
assumptions for VBA are valid in the context of evaluating the performance HPV tests. To 131 
address this question, we conducted a literature search to identify studies that diagnosed both 132 
HPV-positive and –negative CIN2+ for a pooled analysis to examine whether in this context the 133 
basic tenet that FN and TP cases are biologically equivalent and therefore can be used to correct 134 
via VBA the clinical performance of HPV tests for screening to prevent cervical cancer.  135 
 
8 
 
Methods 136 
An extensive literature search, using the following search string “(HPV OR (human AND 137 
papillomavirus)) AND ((verification AND bias) OR (Cytology OR PAP OR VIA or visual 138 
inspection) AND (CIN2 OR "CIN 2" OR CIN-2 OR CIN3 OR "CIN 3" OR CIN-3 OR precancer 139 
OR pre-cancer))” was conducted in Ovid MEDLINE, PubMed Central®, and Google Scholar for 140 
all relevant studies in the English language. The goal of the search was to identify studies 141 
evaluating HPV tests in which the study design included colposcopic referral of HPV-positive 142 
and –negative CIN2+, with the latter as the result of direct referral or the result of another assay 143 
testing positive (while the primary study HPV test was negative). Studies were included if 144 
histologic endpoints were available and either summary statistics or de-identified individual data 145 
were provided for the CIN2+ cases diagnosed in the study. 146 
Proportions of diagnoses (CIN2 vs. CIN3 for primary or secondary endpoint diagnoses), other 147 
tests (e.g., a second HPV test or visual inspection after acetic acid (VIA)), cytology (i.e., high-148 
grade cytology vs. not), and colposcopic impression (i.e., high-grade vs. not) were compared 149 
between HPV-positive and –negative-CIN2+ using Metaprop (22), a STATA command for 150 
pooling binomial data. We classified HPV genotyping results hierarchically according to cancer 151 
risk (23, 24): HPV16 positive, else HPV16 negative but positive for other high-risk HPV types, 152 
else negative for all high-risk HPV types but positive for low-risk HPV types, else negative for 153 
all HPV genotypes tested (HPV16 > other high-risk HPV > low-risk HPV > negative). However, 154 
we tested proportion of each HPV genotype category for HPV-negative and HPV-positive 155 
CIN2+ by running separate binomial models for each i.e., each category was independent. Thus 156 
the sum of the HPV categories is not constrained to equal one (unity). 157 
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STATA (version 15.1; College Station, TX, USA) was used for all analyses. A p<0.05 was 158 
considered statistically significant.  159 
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Results 160 
Nineteen studies included 3,396 cases of CIN2+, 3,089 (91.0%) that tested positive and 307 161 
(9.0%) that tested negative by the primary study HPV test, were included in this analysis (Table 162 
1) (25-43). We included one study conducted in human immunodeficiency virus (HIV)-infected 163 
women, in which women with abnormal cytology, a positive VIA, and a 25% random sample of 164 
the cytology- and VIA-negatives were referred to colposcopy and HPV testing was done on all 165 
women but was not the basis of referral to colposcopy (40). Exclusion of this study did not 166 
appreciably change our findings. We also included colposcopy referral arm of one RCT for the 167 
management of minor cytological abnormalities (26). Exclusion of this study did not appreciably 168 
change our findings. 169 
Table 2 summarizes the main results. Women diagnosed with HPV-positive CIN2+ were less 170 
likely to be aged 40 years and older compared with HPV-negative CIN2+ (0.30 vs. 0.34, 171 
respectively, 19 studies, p=0.03). There was no difference in the proportion of women who 172 
smoked (9 studies, p=0.62) between those diagnosed with HPV-positive and –negative CIN2+. 173 
Figure 1-4 shows forest plots (blobbograms) for some of the main comparisons, of the analysis. 174 
Women with a HPV-positive CIN2+ were two-fold more likely than those with HPV-negative 175 
CIN2+ to have a diagnosis of CIN3+ (vs. CIN2) (18 studies, 0.56 vs. 0.24, respectively, 176 
p<0.001) (Figure 1). HPV-positive CIN2+ was three-fold more likely than HPV-negative CIN2+ 177 
to have an antecedent (referral) HSIL+ cytology (15 studies, 0.34 vs. 0.10, respectively p<0.001) 178 
(Figure 2). HPV-positive CIN2+ was less likely than HPV-negative CIN2+ to be VIA positive 179 
(6 studies, 0.57 vs. 0.83, respectively p<0.001) (Figure 3); exclusion of the Chile study (38), 180 
which referred HPV-negative women to colposcopy based on a stratified sampling of VIA 181 
results (all VIA positives [n=117], VIA indeterminate [n=110], and VIA negative with cervical 182 
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cancer risk factors [n=68]) did not appreciably change these results (5 studies, 0.63 vs. 0.81, 183 
respectively, p<0.001). HPV-positive CIN2+ was more likely than HPV-negative CIN2+ to have 184 
a high-grade colposcopic impression (13 studies, 0.30 vs. 0.18, respectively, p=0.03) (Figure 4). 185 
Exclusion of the two studies (31, 32) in which the colposcopists were not masked to the HPV 186 
results did not appreciably change the relationship of HPV status and the appearance of high-187 
grade colposcopic impression. 188 
In 6 studies, a second clinical HPV test was done on the same cervical specimen and was more 189 
likely to test positive for HPV-positive CIN2+ compared to the HPV-negative CIN2+ (0.97 vs. 190 
0.36, respectively, p<0.001) (Table 2 and Supplemental Figure 1). In 4 studies, HPV testing of 191 
self-collected cervicovaginal specimens were also more likely to be positive for HPV-positive 192 
CIN2+ compared to the HPV-negative CIN2+ although the differences were surprisingly small 193 
(0.95 vs. 0.84, respectively, p<0.001) (Table 2 and Supplemental Figure 1). 194 
A secondary analysis was conducted on the HPV genotyping results that were available from 9 195 
studies (26, 30, 33-35, 37, 39, 42, 43), of which one (39) conducted HPV genotyping on biopsied 196 
tissue that led to the diagnosis (Table 2 and Supplemental Figure 2). HPV genotyping results 197 
in the individual studies were grouped hierarchically into broad categories of cancer risk 198 
(HPV16>other high-risk HPV>low-risk HPV>negative) (n.b., because we ran separate models 199 
for each HPV genotyping category, the sum of categories does not equal unity and therefore the 200 
results do not represent attributable fractions of each category. Only the proportion within HPV 201 
genotyping category can be compared between HPV-negative and HPV-positive CIN2+.). HPV-202 
positive CIN2+ was more likely than HPV-negative CIN2+ to test positive for HPV16 (0.46 vs. 203 
0.09, respectively, p<0.001) and other high-risk HPV genotypes (0.49 vs 0.32, respectively, 204 
p<0.001). HPV-positive CIN2+ was less likely than HPV-negative CIN2+ to test positive for 205 
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low-risk HPV genotypes (0.00 vs. 0.13, respectively, p<0.001). HPV-positive CIN2+ was less 206 
likely than HPV-negative CIN2+ to test negative for any HPV genotype (0.02 vs. 0.33, 207 
respectively, p<0.001). Exclusion of the one study (30) in which the HPV test that was under 208 
evaluation also provided the HPV genotyping data for these correlative analyses did not 209 
appreciably change the results. 210 
Several studies included marker/biomarker testing results that, while not sufficiently commonly 211 
done for data pooling, are summarized in Table 3. Data on p16 immunohistochemistry of the 212 
CIN2+ was available from two studies. One study found that HPV-positive CIN2+ was 213 
significantly more likely to test positive by p16 immunohistochemistry than HPV-negative 214 
CIN2+ (37) while the other found similar but non-significant difference (34). There was no 215 
difference in detection of HPV16/18/45 E6 in HPV-positive CIN2+ as compared to HPV-216 
negative CIN2+ based on one study (39).  217 
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Discussion 218 
We combined data from several epidemiologic studies and clinical trials of HPV testing to 219 
compare the distribution of other biomarkers of cervical cancer risk among HPV-positive and 220 
HPV-negative CIN2+. The latter was detected because the source studies included in their design 221 
a protocol to perform a verification-bias adjustment (e.g., a sample of HPV-negative women 222 
were referred to colposcopy) or because referral to colposcopy was based on the positive result 223 
of another (non-HPV) test. We found evidence that the HPV-negative CIN2+ is a distinct 224 
biological and clinical entity compared with HPV-positive CIN2+ and thus would likely carry 225 
lower invasive cervical cancer risk. While the validity-seeking exercise of the VBA is meant to 226 
bring sensitivity and specificity estimates closer to the theoretical parameters that represent the 227 
performance of the test in detecting the full spectrum of disease, it introduces a departure from 228 
the real-world conditions of screening practice. The distortion comes from ignoring the 229 
heterogeneity of current histopathologic standards of cervical precancer, specifically leading to 230 
the unintended clinical consequence of considering TP-test and FN-test cases equivalent. That is, 231 
the VBA correction, when applied to HPV testing, makes FN-test cases become an 232 
overrepresentation in the totality of discoverable true disease, leading to an underestimation of 233 
the test performance relative to benchmarks of clinical utility. Strategies for better estimation of 234 
test performance are discussed below. 235 
Our analysis shows that HPV-negative CIN2+ results were a mixture of CIN2+ diagnoses that 1) 236 
tested falsely negative (FN) for high-risk HPV, 2) were caused by HPV types not considered of 237 
high carcinogenic risk, and 3) epithelial changes that have the appearance of CIN2/3 but are 238 
benign mimics, such as immature squamous metaplasia, atrophy, reparative epithelial changes, 239 
and/or tangential sectioning on routine staining (44-46). FN-test CIN2+ are those that the HPV 240 
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test should have detected and as such, should count against its clinical performance. These FN-241 
test CIN2+ include some CIN2/3 that are likely to be low-volume, low-area that as a 242 
consequence are poorly sampled and test falsely HPV negative i.e., they are truly HPV-positive 243 
CIN2/3 but test HPV negative due to poor representation in the cervical exfoliative sample (45, 244 
47). This subset of FN-test CIN2+ are true test failures and cannot be discounted. 245 
We observed that only about one-third of the HPV-negative CIN2+ tested high-risk HPV 246 
positive by a second, clinical test whereas virtually all of the HPV-positive CIN2+ tested 247 
positive. Thee data confirm that HPV-negative CIN2+ cases included some FN-test CIN2+ and 248 
TN-test CIN2+. Interestingly, in the small sub-group of studies, the proportion of HPV-negative 249 
CIN2+ that tested high-risk HPV positive on a self-collected cervicovaginal was high albeit still 250 
less than the for HPV-positive CIN2+. We speculate that the high proportion of high-risk HPV 251 
positivity for the self-collected specimen among the HPV-negative CIN2+ is due in part to the 252 
detection of vaginal HPV infections unrelated to the CIN2+ (48, 49). 253 
Because those CIN2+ diagnoses caused by other types not classified as high-risk HPV are very 254 
unlikely to cause invasive cancer (50, 51), these cases should not be counted strictly as test 255 
failures. The goal of screening is ultimately to prevent cancer, via the detection of cervical pre-256 
cancer that have significant propensity to progress to cancer, thus enabling treatment to arrest 257 
their development. Thus, these HPV types should not be included in clinical HPV tests as they 258 
can have the potential to classify more women as HPV positive and result in diagnosis of CIN2 259 
with low progression potential. As a consequence, these diagnoses potentially would result in 260 
additional (unnecessary) treatments, which is a risk factor for pre-term delivery (52, 53), without 261 
the compensatory benefit of cancer prevention. A case-in-point is the inclusion of HPV66 in the 262 
current clinical high-risk HPV tests, which was momentarily believed to be another high-risk 263 
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HPV type (54). However, it is now recognized that HPV66 very rarely causes cancer but does 264 
increase the test positivity (50, 51, 54). 265 
Some HPV-negative CIN2+ could be the result of abnormalities of smaller volume and/or lower 266 
viral shedding. We would expect that these, like truly HPV-negative CIN2+, would be of lower 267 
invasive potential. Larger CIN3, for example, found in older women have been hypothesized to 268 
have much greater invasive potential than early, small, incipient CIN3 diagnosed in young 269 
women (55, 56). 270 
Finally, some epithelial changes appear to be visual and morphological look-alikes of CIN2/3 but 271 
may be less likely to represent true precursors to cancer (44, 45). Like those CIN2/3 caused by 272 
HPV types not classified as high risk, these “mimics” are best left undiagnosed, given that they 273 
will not cause cancer, and thereby avoiding any unnecessary treatment. These changes may be 274 
due in part to a common cause, atrophic cervical epithelial changes in peri- and post-menopausal 275 
women. These epithelial changes appear as acetowhitened cervical tissue, which are called 276 
positive by VIA and giving colposcopic impression of cervical abnormality, albeit not high-277 
grade, leading to a biopsy and diagnosis. 278 
Another implication of our findings is that the endpoint of CIN2/3 is very heterogeneous in its 279 
clinical importance i.e., invasive cervical cancer risk, likely even more so than the heterogeneity 280 
of CIN3, a more certain diagnosis of pre-cancer (55, 56). Thus, simple accounting of the detected 281 
and missed CIN2+ does not reflect accurately the true sensitivity of a cervical screening test to 282 
prevent cervical cancer. Rather than use crude sensitivity, a measure of clinically-relevant 283 
sensitivity, one in which all endpoints of CIN2/3 (regardless of the result of the HPV test being 284 
evaluated) are weighted according to their invasive cervical cancer risk or potential, should be 285 
used: 286 
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(∑ 𝑥𝑖
𝑦
𝑖=1 𝑛𝑖)𝑝𝑜𝑠
(∑ 𝑥𝑖𝑛𝑖
𝑦
𝑖=1 )𝐴𝑙𝑙
 
in which xi is the specific weighting factor and ni is the number of abnormalities with the 287 
characteristics i. 288 
However, we know very little about the factors that determine invasive potential of CIN2/3 and 289 
therefore their corresponding weighting. Almost certainly, how long the CIN2/3 has been present 290 
(a surrogate for which is the woman’s age), its size (56), the causal HPV type, whether it is CIN2 291 
or CIN3, if the woman has human immunodeficiency virus co-infection and her immune 292 
competency (57), etc. likely influence the risk of invasion. Unfortunately, we do not yet know 293 
how to weight the invasive risk of CIN2/3 for many of these factors. 294 
However, one possible way to improve the estimated performance for the prevention of cervical 295 
cancer is to weight individual CIN2/3 diagnoses based on the HPV type present. Doing so, the 296 
above equation then would be written as: 297 
(∑ 𝑋𝐻𝑃𝑉𝑖
𝑦
𝑖=1 𝑛𝐻𝑃𝑉𝑖)𝑝𝑜𝑠
(∑ 𝑋𝐻𝑃𝑉𝑖𝑛𝐻𝑃𝑉𝑖
𝑦
𝑖=1 )𝐴𝑙𝑙
 
in which XHPVi is the weighting factor for HPV type i. 298 
Intuitively, it is clear that HPV16 is the most important type for causing cancer, i.e., more 299 
carcinogenic than all other types (23, 24). Likewise, prophylactic vaccines against HPV16 and 300 
HPV18 are projected to prevent approximately 70% of cervical cancers, not based on the number 301 
of percentage of HPV infections that are HPV16 and/or HPV18 but the fraction of cervical 302 
cancers they cause. Therefore, more importance should be placed on the detection or missed 303 
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detection of HPV16-related cervical abnormalities than comparable abnormalities caused by 304 
other HPV types.  305 
To this point, we note that the HPV-negative CIN2+ cases from this analysis were unlikely to 306 
test HPV16 positive whereas approximately half of the HPV-positive CIN2+ tested HPV16 307 
positive, which is generally the expected proportion of HPV16 positives (51). Each individual 308 
study included in this analysis found a greater proportion of HPV16 among the HPV-positive 309 
CIN2+ than HPV-negative CIN2+. This was true even for the study (39) in which the tissues 310 
were HPV genotyped, which found 17% of the HPV-negative CIN2+ and 62% of the HPV-311 
positive CIN2+ tested HPV16 positive, which cannot be explained by differences in viral 312 
shedding.  Again, these data support the inference that these HPV-negative CIN2+ have lower 313 
invasive cancer risk on the whole and a significant proportion carry virtually zero risk. Although 314 
we do not have prospective data to calculate type-specific transition probabilities from CIN2 or 315 
CIN3 to cancer for each HPV type, HPV type-specific weights might be derived from cross-316 
sectional studies of HPV types and grade of disease as crude approximations. For example, using 317 
data from a large meta-analysis by Guan et al. (51), the ratio of invasive cervical cancer to CIN3 318 
is 1.08 for HPV16 and 0.31 for HPV68. Therefore, a HPV68-related CIN3 should be discounted 319 
(weighted) by 0.29 compared to a HPV16-related CIN3; the weighting and that HPV16-related 320 
CIN3 is more common than HPV68-related CIN3 might reasonably approximate the relative 321 
importance of the two HPV type-specific CIN3. Using these same or similar data, the 322 
abnormality could be discounted further (weighted less) if it is CIN2 rather than a CIN3 323 
diagnosis. Although these weighting factors are likely to be rough approximations of the relative 324 
importance of abnormalities by HPV type and diagnosis, using them would provide a more 325 
accurate representation of the potential value in detecting a given abnormality and initiating 326 
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treatment than treating all CIN3 equally or worse yet, all CIN2/3 equally. Future clinical 327 
evaluations of individual HPV tests might consider such an approach. 328 
As corollary of our observations with cervical cancer screening, we propose that the same 329 
principle could be applied to other screening interventions focused on detection of precursors of 330 
other cancers, with the weighting informed by either empirical (natural history) data or modeling 331 
on the invasive cancer risk. For example, ductal carcinoma in situ of the breast is known to be 332 
heterogeneous in terms of cancer risk and in certain lower-risk groups, analogous to surveillance 333 
rather than immediate treatment of CIN2 (58), treatment is being “de-escalated” (59). Likewise, 334 
colorectal cancer risk following diagnosis of polyp(s) varies by size, type (adenomatous vs. non- 335 
adenomatous), number, histological type, and location of the polyp(s) as well as patients’ age 336 
and sex (60-62). 337 
The most important limitation of this analysis is that the actual invasive potential of each CIN2/3 338 
diagnosed is unknown i.e., correlative measures were used to judge the relative clinical 339 
importance of each CIN2+ diagnosis. It is unethical to observe the development of cervical 340 
cancer from high-grade cervical abnormalities as was previously done (55). Although CIN2 341 
diagnosed in women under the age of 30 years can be followed according to certain guidelines 342 
(58) because it is highly regressive (63), CIN3 is typically treated by excision therapies to avert 343 
invasive cancer. Even CIN3, the most severe pre-malignant cervical diagnosis, is not pre-cancer 344 
per se i.e., it is not synonymous with having or developing invasive cervical cancer as only 345 
approximately one-third of CIN3 diagnosed in older women will become invasive cervical 346 
cancer if untreated (55). We therefore used biomarkers that are associated with higher risk of 347 
cancer rather than directly observing which CIN2+ would develop into frank cancer. 348 
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There were other important limitations, notably heterogeneity between studies e.g., differences in 349 
HPV tests used and the percentage of sampling and selection of cases among the HPV-negative 350 
CIN2/3. There were not enough studies to conduct separate stratified analyses for each HPV test; 351 
however, many of the HPV tests used in studies included in this analysis have been shown to 352 
have good agreement with one another because they were developed in accordance with 353 
international standards for clinical HPV tests (64). A study using a less sensitive HPV test would 354 
have resulted in more FN-CIN2+ that are clinically relevant. 355 
In addition, some data were not available to us and therefore we cannot call this a true systematic 356 
review. Although there was significant heterogeneity in the relative and absolute effects between 357 
studies, patterns/trends were generally consistent across studies. We therefore think that it is 358 
unlikely that the few missing studies biased our findings, although we cannot rule out this 359 
possibility entirely either. 360 
In conclusion, we pooled data across many studies to demonstrate that HPV-negative CIN2+ 361 
systematically were less like to test positive for any biomarkers associated with invasive cancer 362 
risk compared to HPV-positive CIN2+. Thus, the use of HPV-negative CIN2+ in VBA 363 
calculations may result in systematic over-correction of sensitivity for CIN2+ due to presumptive 364 
FN HPV results. Although VBA is an established approach to derive numerically correct 365 
estimates of test performance in screening studies, the corrective effect comes at the expense of 366 
over-estimating the clinical relevance of insipient, non-progressive CIN2/3. The true limitation 367 
of VBA for HPV testing validation is not VBA itself, which is mathematically correct, but rather 368 
our limited ability to differentiate by any means the clinically relevant from the irrelevant 369 
CIN2/3. Therefore, its use must be cautiously interpreted because the VBA correction distorts the 370 
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disease detection reality by giving excessive value to low-grade disease i.e., false-positive 371 
diagnoses.   372 
Biomarkers applied to the diagnostic tissue may help. However, p16 immunohistochemistry, 373 
which is recommended for differentiating high-risk and low-risk CIN2 (44), does so imperfectly 374 
(65). Hence, using VBA, with or without p16 immunohistochemistry, still will result in some 375 
underestimation of clinical performance of a cervical cancer screening test, such as an HPV 376 
assay. A more general framework of mathematical adjustment of the clinical performance for the 377 
detection of pre-invasive disease, using weighting based on the risk of invasive disease derived 378 
from the natural history of the cancer, may provide a better estimate of the true effectiveness for 379 
an intervention to prevent cancer. 380 
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Table 1. List of studies included in these analyses. Abbreviations: HC, Hybrid Capture; HC2, Hybrid Capture 2; HR-HPV, high-risk 551 
human papillomavirus; Cyto+, borderline or atypical squamous cells of undetermined significance or more severe cytology; ≥ASC-552 
US, ASC-US or more severe; RS, random sample. 553 
Study 
Locationreference 
Study 
Population 
Type 
Enrollment 
Period 
Enrolled 
Population 
(Age 
Criteria) 
Main 
HPV Test 
Primary 
Histological 
Endpoint 
Diagnosis* Cytology VIA 
Other (Clinical) 
Tests 
Colposcopy 
Referral Criteria 
HPV-positive 
CIN2+ 
HPV-negative 
CIN2+ 
 
N 
Age 
(mean; 
median) 
(Years) N 
Age 
(mean; 
median) 
(Years) p
∞
 
England (25) Screening 1994-1997 
2,988 
(≥35 years) 
HC 
Consensus 
Review 
Yes No 
Yes; PCR and HC 
MY09/11 PCR 
Cyto+ and/or HPV+ 
(PCR) 
23 44.4;43 3 41.0;42 0.6 
USA (26) 
Referral 
for ASCUS 
or LSIL 
Pap** 
1996-1998 
1,836** 
(≥18 years) 
HC2 
Consensus 
Review ‡ 
Yes No No All** 222 24.6; 23 16 25.6; 23.5 0.5 
Canada (27) Screening 1996-1998 
2,098 
(18-69 years) 
HC//HC2 
Community 
Diagnosis 
Yes No No Cyto+ and/or HPV+ 26 28.1; 27 5 31.2; 30 0.5 
Germany (28) Screening 1996-1998 
4,761 
(≥35 years) 
GP 5+/6+ 
PCR 
Consensus 
Review 
Yes No PAPNET All 108 30.8; 31 6 30.0; 32.5 0.8 
China (29) Screening 1999 
1,997 
(35-45 years) 
HC2 
Study 
Pathologist 
Yes Yes Self-Collection All 82 39.5; 40 2 38.5; 38.5 0.6 
USA (30) Screening 1997-2000 
4,075 
(18-50 years) 
MY09/11 
PCR 
Study 
Pathologist 
Yes No No 
Cyto+ and/or 
HPV+£; ~10% RS of 
Screen- 
190 25.2; 23.5 26 24.0; 24.5 1.0 
China (31) Screening 2001-2002 
8,497 
(27-56 years) 
HC2 
Study 
Pathologist 
Yes No Self-Collection All 306 42.0; 42 10 40.8; 40 0.5 
England (32) Screening 1998-2001 
11,085 
(30-60 
years); 
HC2 
Consensus 
Review 
Yes No No 
Cyto+ and/or HPV+; 
~5% (n=414) screen-
negatives 
87 36.2;34 49 47;49 0.02 
India (33) Screening 2005-2007 
2,331 
(≥25 years) 
HC2 
Two 
independent 
reads; worst 
histology 
Yes Yes Linear Array 
Cyto+, HC2+, and/or 
VIA+; 20% RS of 
Screen- 
14 41.1; 37.5 4 37.5; 37.5 0.7 
China (34) Screening 2009-2010 
8.556 
(25-59 years) 
HC2 
Consensus 
Review 
Yes No 
Cervista; MALDI-
TOF; Self-
Collection 
Cyto+ and/or HPV+ 
by Cervista and/or 
MALDi-TOF on 
self-collection and/or 
provider collection 
and/or HC2 on 
provider collection 
225 39.5;39 11 37.4; 36 0.4 
France (35) Screening 2008-2009 
4,950 
(20-65 years) 
HC2 
Consensus 
Review
¥
 
Yes No Aptima 
Cyto+ and/or HPV+ 
by HC2 and/or 
Aptima 
96 34.9; 33 4 44.3; 44 0.04 
Democratic 
Republic of the 
Congo (36) 
Screening 2003-2004 
1,699 
(≥30 years) 
HC2 
Study 
Pathologist 
Yes Yes No All 21 59.7; 45 3 62.8; 44 0.9 
USA (37) Screening 2008-2009 41,955 cobas Consensus Yes No Linear Array; Cyto+ and/or HPV+ 578 32.9; 31 63 37.6; 36 0.003 
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(≥25 years) Review AMPLICOR by AMPLICOR 
and/or Linear Array 
positive; ~2.5% RS 
of Screen- 
Chile (38) Screening 2009-2010 
8,309 
(25-64 years) 
HC2 
Community 
Pathology 
Yes Yes No 
Cyto+, HC2+, and/or 
VIA+; 68 high-risk, 
screen–negative 
women 
91 36.8; 25 5 36.0; 35 1.0 
China (39) Screening 2010-2011 
7,541 
(25-65 years) 
HC2 
Study 
Pathologist 
No Yes 
Self-collected 
specimens tested 
by HC2 and 
careHPV; 
provider-collected 
specimens tested 
by careHPV; 
HPV16/18/45 E6 
Test; HPV 
genotyping of the 
biopsy by 
SPF10/LiPA 
Women who tested 
positive for any of 
the 6 screening 
tests conducted 
(VIA, HPV E6, and 
HC2 and careHPV 
on clinician-
collected and self-
collected 
specimens); ~10% 
RS of Screen- 
138 46.5; 46.5 6 47.7; 45.5 0.8 
South Africa 
(40) 
Screening 2009-2011 
1,202† 
(18-65 years) 
HC2 
Community 
Pathology 
Yes Yes No 
Cyto+ and/or VIA+; 
~25% RS of Screen- 
291 37.0; 36 21 39.6; 40 0.1 
India (41) Screening 2010-2014 
39,740 
(30-60 years) 
HC2 
Consensus 
Review 
No Yes No HC2+ and/or VIA+ 202 36.0; 34 74 42.2; 40 <0.001 
Canada (42) Screening 2002-2005 
10,154 
(30-69 years) 
HC2 
Community 
Pathology‡ 
Yes No Linear Array 
≥ASC-US cytology, 
HPV+; ~10% (St. 
John’s) and ~20% 
(Montreal) RS of 
Screen- 
71 36; 37.0 11 50; 47.2 0.002 
USA (43) Screening 2013-2015 
33,858 
(≥21 years) 
Onclarity 
Consensus 
Review 
Yes No 
HC2; Onclarity on 
ThinPrep 
Specimen; 
bidirectional 
Sequencing for 
HPV genotyping 
≥ASC-US cytology, 
HPV+ by Onclarity 
on SurePath and/or 
ThinPrep) and/or 
HC2 on ThinPrep; 
~5% RS of Screen-  
316 32;34.0 36 25; 36.9 0.05 
*Single=biopsy diagnosis based on a review by single pathologist as part of routine care or by a single study pathologist; Consensus=panel review 554 
of the biopsy diagnosis by two or more pathologists and some method of adjudication of discordant results 555 
**Only those in the immediate colposcopy arm were considered in this analysis 556 
†Women living with HIV 557 
£HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and/or HPV68 positive 558 
‡Worst diagnosis on biopsy or excised tissue 559 
∞Kruskal-Wallis test for differences in the median age 560 
¥
Diagnoses of CIN2+ were confirmed by p16 immunohistochemistry
  
561 
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Table 2. Summary of results of the pooled analyses to compare human papillomavirus (HPV)–positive and HPV-negative cervical 562 
intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+). 563 
 564 
 Number 
of Studies 
HPV-positive CIN2+ HPV-negative CIN2+ 
p  N Fraction (95%CI) N Fraction (95%CI) 
Demographics       
Aged ≥40 years at Diagnosis 19 3,089 0.30 (0.29-0.32) 307 0.34 (0.28-0.41) 0.03 
Ever Smoked 9 1,873 0.40 (0.38-0.42) 185 0.30 (0.30-0.46) 0.6 
Clinical Correlates       
CIN3+ (Primary Endpoint) 18 3,062 0.56 (0.54-0.58)  304 0.24 (0.19-0.30) <0.001 
Antecedent HSIL+ Cytology 15 2,552 0.34 (0.32-0.36) 217 0.10 (0.05-0.15) <0.001 
VIA positive 6 739 0.57 (0.53-0.60)  113 0.83 (0.73-0.90) <0.001 
High-Grade Colposcopic Impression 13 1,800 0.30 (0.28-0.33) 174 0.18 (0.12-0.30) 0.03 
Other Pathology Review 7 1,471 0.51 (0.48-0.53) 135 0.42 (0.33-0.52) 0.09 
Other Clinical HPV* 6 1,449 0.97 (0.96-0.98) 134 0.39 (0.31-0.48) <0.001 
Self-Collection and HPV Testing
**
 4 721 0.95 (0.93-0.96) 58 0.84 (0.71-0.94) <0.001 
HPV Genotyping Category
†‡ 
      
HPV16 
9 1,556 
0.46 (0.43-0.48) 
261 
0.09 (0.05-0.14) <0.001 
Other High-Risk HPV 0.49 (0.47-0.52) 0.32 (0.26-0.38) <0.001 
Low-Risk HPV 0.00 (0.00-0.01) 0.13 (0.09-0.18) <0.001 
HPV Negative 0.02 (0.01-0.02) 0.33 (0.27-0.39) <0.001 
*Results from provider-collected cervical specimens tested by AMPLICOR (26, 37), MALDI-TOF (34), Aptima (35), careHPV (39), 565 
and HC2 (43) 566 
**
Self-collected cervicovaginal specimens tested by HC2 (29, 31, 39) and MALDI-TOF (34) 567 
†
HPV genotype results were categorized hierarchically according to cancer risk:  568 
‡
The totals do not add to 100%, even though individual studies add up to 100%. A separate binomial model was run for each HPV 569 
genotyping category and therefore independent. Thus the sum of the HPV categories is not constrained to equal one (unity).  570 
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Table 3. Comparison of results of biomarker testing from individual studies between human 571 
papillomavirus (HPV)–positive and HPV-negative cervical intraepithelial neoplasia grade 2 or 572 
more severe diagnoses (CIN2+). 573 
 574 
 HPV-positive CIN2+ HPV-negative CIN2+ 
p 
 N %Positive N %Positive 
p16 
immunohistochemistry*(37) 52 84.6% 62 61.3% 0.007 
p16 immunohistochemistry 
(34) 161 96.3% 6 83.3% 0.2 
HPV16/18/45 E6 (39) 138 42.8% 6 33.3% 1.0 
*Only a stratified sample of cases were tested (66). 575 
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Figure Legends: 577 
 578 
Figure 1. Forest plots for the proportion of cervical intraepithelial neoplasia (CIN) grade 2 or 579 
more severe (CIN2+) diagnoses that had a CIN grade 3 or more severe (CIN3+) diagnosis, 580 
stratified on the human papillomavirus (HPV) test result.  581 
 582 
Figure 2. Forest plots for the proportion of cervical intraepithelial neoplasia (CIN) grade 2 or 583 
more severe (CIN2+) diagnoses that had an antecedent high-grade squamous intraepithelial 584 
lesion (HSIL) or more severe cytologic interpretation (HSIL+), stratified on human the 585 
papillomavirus (HPV) test result.  586 
 587 
Figure 3. Forest plots for the proportion of cervical intraepithelial neoplasia (CIN) grade 2 or 588 
more severe (CIN2+) diagnoses that was positive by visual inspection by acetic acid (VIA), 589 
stratified on the human papillomavirus (HPV) test result.  590 
 591 
Figure 4. Forest plots for the proportion of cervical intraepithelial neoplasia (CIN) grade 2 or 592 
more severe (CIN2+) diagnoses that had a high-grade colposcopic impression, stratified on the 593 
human papillomavirus (HPV) testing result.  594 
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